drugset / Trial / NCT04135677

Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO

NCT04135677

Phase 4 Unknown 826 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

The objective of this study is to assess the efficacy and safety different dosage of rivaroxaban application versus dual antiplatelet therapy after successful closure of left atrial appendage using the LAMBRE device.

Timeline

Start
2022-11-11
Primary completion
2024-10-01
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg
Subject Clopidogrel Small molecule 75 mg
Subject Rivaroxaban Other / unclassified 20 mg